News | June 18, 2026
Bayer seals $300 million Perfuse deal
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
The launch comes against the backdrop of a significant public health burden
The development comes as stroke remains one of the world’s biggest health threats
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Subscribe To Our Newsletter & Stay Updated
